Fiera Capital Corp cut its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 10.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,664,871 shares of the biotechnology company’s stock after selling 184,345 shares during the quarter. Fiera Capital Corp owned approximately 2.27% of Momenta Pharmaceuticals worth $28,136,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MNTA. Louisiana State Employees Retirement System lifted its holdings in Momenta Pharmaceuticals by 2.3% during the first quarter. Louisiana State Employees Retirement System now owns 26,300 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 600 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in Momenta Pharmaceuticals by 179.3% during the first quarter. Nationwide Fund Advisors now owns 112,712 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 72,361 shares during the last quarter. Strs Ohio purchased a new stake in Momenta Pharmaceuticals during the first quarter valued at about $221,000. Russell Investments Group Ltd. lifted its holdings in Momenta Pharmaceuticals by 749.5% during the first quarter. Russell Investments Group Ltd. now owns 160,960 shares of the biotechnology company’s stock valued at $2,148,000 after purchasing an additional 142,012 shares during the last quarter. Finally, Great West Life Assurance Co. Can lifted its holdings in Momenta Pharmaceuticals by 5.9% during the first quarter. Great West Life Assurance Co. Can now owns 89,021 shares of the biotechnology company’s stock valued at $1,183,000 after purchasing an additional 4,936 shares during the last quarter. 93.86% of the stock is currently owned by institutional investors and hedge funds.

MNTA has been the topic of several recent research reports. Barclays PLC downgraded shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $20.00 to $17.00 in a report on Monday, May 22nd. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Maxim Group set a $6.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $26.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, August 3rd. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the stock. Momenta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $16.63.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total value of $62,028.12. Following the transaction, the president now directly owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 43,996 shares of company stock worth $735,755 over the last three months. Insiders own 4.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Fiera Capital Corp Sells 184,345 Shares of Momenta Pharmaceuticals, Inc. (MNTA)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://theolympiareport.com/2017/09/14/fiera-capital-corp-sells-184345-shares-of-momenta-pharmaceuticals-inc-mnta.html.

Shares of Momenta Pharmaceuticals, Inc. (MNTA) opened at 17.40 on Thursday. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.75 and a 12 month high of $19.90. The company’s market capitalization is $1.29 billion. The stock’s 50 day moving average price is $16.34 and its 200 day moving average price is $15.48.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.50). The business had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $24.64 million. Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period last year, the firm posted ($0.31) earnings per share. On average, analysts forecast that Momenta Pharmaceuticals, Inc. will post ($1.24) EPS for the current year.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.